A randomised, prospective phase II study of pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in a shortened treatment of mild-to-moderate tuberculosis compared with standard of care

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518772-32-00

Acronym

HIGH-SHORT RP

Enrollment

Registered

2024-10-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Brief summary

The primary variable is the area under concentration and time curve (AUC0-24h) for high-dose RIF in a combination regimen with high-dose PZA on day 1 after the first dose and at week 2.

Interventions

DRUGPYRAZINAMIDE

DRUGRIFAMPICIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary variable is the area under concentration and time curve (AUC0-24h) for high-dose RIF in a combination regimen with high-dose PZA on day 1 after the first dose and at week 2.	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026